erlotinib hydrochloride has been researched along with thiazolyl blue in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (thiazolyl blue) | Trials (thiazolyl blue) | Recent Studies (post-2010) (thiazolyl blue) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 4,625 | 20 | 1,230 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishikawa, D; Matsumoto, K; Nakagawa, T; Nakamura, T; Nanjo, S; Sano, T; Takeuchi, S; Yamada, T; Yano, S | 1 |
| Liu, YH; Zhu, WL | 1 |
2 other study(ies) available for erlotinib hydrochloride and thiazolyl blue
| Article | Year |
|---|---|
The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
Topics: Animals; Antineoplastic Agents; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, SCID; Mutation; Neoplasm Transplantation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; Tetrazolium Salts; Thiazoles; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
Effects of kinase insert domain receptor (KDR) gene silencing on the sensitivity of A549 cells to erlotinib.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Cell Proliferation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Silencing; Humans; Lung Neoplasms; RNA, Messenger; RNA, Small Interfering; Tetrazolium Salts; Thiazoles; Vascular Endothelial Growth Factor Receptor-2 | 2015 |